KR20060118514A - 증식성 질병의 치료를 위한 조합 - Google Patents

증식성 질병의 치료를 위한 조합 Download PDF

Info

Publication number
KR20060118514A
KR20060118514A KR1020067010335A KR20067010335A KR20060118514A KR 20060118514 A KR20060118514 A KR 20060118514A KR 1020067010335 A KR1020067010335 A KR 1020067010335A KR 20067010335 A KR20067010335 A KR 20067010335A KR 20060118514 A KR20060118514 A KR 20060118514A
Authority
KR
South Korea
Prior art keywords
agent
biological activity
reduces
compound
protein tyrosine
Prior art date
Application number
KR1020067010335A
Other languages
English (en)
Korean (ko)
Inventor
엠. 제임스 니콜스
마가렛 에스 리
커티스 키이스
얀첸 쟝
Original Assignee
콤비네이토릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by 콤비네이토릭스, 인코포레이티드 filed Critical 콤비네이토릭스, 인코포레이티드
Publication of KR20060118514A publication Critical patent/KR20060118514A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020067010335A 2003-11-12 2004-11-09 증식성 질병의 치료를 위한 조합 KR20060118514A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US60/519,551 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
US10/855,130 2004-05-27

Publications (1)

Publication Number Publication Date
KR20060118514A true KR20060118514A (ko) 2006-11-23

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010335A KR20060118514A (ko) 2003-11-12 2004-11-09 증식성 질병의 치료를 위한 조합

Country Status (13)

Country Link
EP (1) EP1689352A2 (ja)
JP (1) JP2007524657A (ja)
KR (1) KR20060118514A (ja)
AR (1) AR046841A1 (ja)
AU (1) AU2004289311A1 (ja)
BR (1) BRPI0416390A (ja)
CA (1) CA2545423A1 (ja)
IL (1) IL175611A0 (ja)
IS (1) IS8496A (ja)
NO (1) NO20062358L (ja)
RU (1) RU2006120491A (ja)
TW (1) TW200526777A (ja)
WO (1) WO2005046607A2 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070865A1 (es) * 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2005046607A3 (en) 2012-12-20
IS8496A (is) 2006-06-02
JP2007524657A (ja) 2007-08-30
RU2006120491A (ru) 2007-12-20
IL175611A0 (en) 2008-04-13
EP1689352A2 (en) 2006-08-16
TW200526777A (en) 2005-08-16
NO20062358L (no) 2006-07-12
CA2545423A1 (en) 2005-05-26
AU2004289311A1 (en) 2005-05-26
AR046841A1 (es) 2005-12-28
WO2005046607A2 (en) 2005-05-26
BRPI0416390A (pt) 2007-02-21

Similar Documents

Publication Publication Date Title
US20060177864A1 (en) Methods for identifying drug combinations for the treatment of proliferative diseases
Alhazzazi et al. Sirtuin‐3 (SIRT3), a novel potential therapeutic target for oral cancer
Bielak-Zmijewska et al. Is DNA damage indispensable for stress-induced senescence?
Castrillo et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages
Yang et al. Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients
Zhou et al. Disrupting the Indian hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis progression in Col2a1-CreER T2; Ihh fl/fl mice
Radbill et al. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression
Rufini et al. Senescence and aging: the critical roles of p53
Haas et al. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium
Stanton et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro
Smith et al. Cellular senescence and its role in white adipose tissue
Kim et al. PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB–dependent pathway
Kidera et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway
McCarthy et al. Basic calcium phosphate crystals activate human osteoarthritic synovial fibroblasts and induce matrix metalloproteinase-13 (collagenase-3) in adult porcine articular chondrocytes
Minashima et al. Lithium protects against cartilage degradation in osteoarthritis
Liang et al. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone
US20120220610A1 (en) Inhibitions of glutaminase c
Baba et al. Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma
McVean et al. A p21waf1‐independent pathway for inhibitory phosphorylation of cyclin‐dependent kinase p34cdc2 and concomitant G2/M arrest by the chemopreventive flavonoid apigenin
Stelma et al. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells
Lee et al. Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice
Furuta et al. High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5
EP3052655B1 (en) Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
Kokkinakis et al. Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress
Abbas et al. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid